Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Itemgruppen: Concomitant Medication Record, Signature of investigator - Concomitant Medication, Adverse event, Signatur of investigator - adverse event

Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) NCT02008721 Short title: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Study Code: PROMESA EudraCT-Number: 2012-000928-18 NCT02008721 Sponsor: Klinikum Großhadern Medical Center University of Munich,Represented by the Medical Director Prof. Dr. med. Burkhard Göke, Marchioninistraße 15 D-81377 Munich Principal Investigator: Prof. Dr. med. Günter Höglinger Department of Neurology, Klinikum rechts der Isar Technische Universität München Ismaninger Str. 22 D-81675 Munich; Contact: Yvonne Rödenbeck Trial Monitoring: Münchner Studienzentrum Klinikum rechts der Isar ,Technische Universität München, Ismaninger Str.22 D-81675 Munich Trial Monitoring: Prof. Dr. rer. nat. Ulrich Masnmann, Institute for Medical Informatics, Biometry and Epidemiology (IBE), Marchioninistraße 15 D-81377 Munich Trial Office: Deutsches Zentrum für Neurodegenerative Erkrankungen e.V., Max-Lebsche Platz 30, D-81377 Munich Source: Priv.-Doz. Dr. med. Johannes Levin Neurologische Klinik Ludwig-Maximilians-Universität München

PROMESA NCT02008721 - Telephone visit 3 (T3)

- 22.12.17 - 1 Formular, 7 Itemgruppen, 19 Datenelemente, 1 Sprache

Itemgruppen: Date of Telephone contact, Adverse event, Concomitant medication, Study medication, Laboratory test, Laboratory test, Signature of investigator

Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) NCT02008721 Short title: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Study Code: PROMESA EudraCT-Number: 2012-000928-18 NCT02008721 Sponsor: Klinikum Großhadern Medical Center University of Munich,Represented by the Medical Director Prof. Dr. med. Burkhard Göke, Marchioninistraße 15 D-81377 Munich Principal Investigator: Prof. Dr. med. Günter Höglinger Department of Neurology, Klinikum rechts der Isar Technische Universität München Ismaninger Str. 22 D-81675 Munich; Contact: Yvonne Rödenbeck Trial Monitoring: Münchner Studienzentrum Klinikum rechts der Isar ,Technische Universität München, Ismaninger Str.22 D-81675 Munich Trial Monitoring: Prof. Dr. rer. nat. Ulrich Masnmann, Institute for Medical Informatics, Biometry and Epidemiology (IBE), Marchioninistraße 15 D-81377 Munich Trial Office: Deutsches Zentrum für Neurodegenerative Erkrankungen e.V., Max-Lebsche Platz 30, D-81377 Munich Source: Priv.-Doz. Dr. med. Johannes Levin Neurologische Klinik Ludwig-Maximilians-Universität München

PROMESA NCT02008721 - Telephone visit 2 (T2)

- 22.12.17 - 1 Formular, 7 Itemgruppen, 19 Datenelemente, 1 Sprache

Itemgruppen: Date of Telephone contact, Adverse event, Concomitant medication, Study medication, Laboratory test, Laboratory test, Signature of investigator

Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) NCT02008721 Short title: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Study Code: PROMESA EudraCT-Number: 2012-000928-18 NCT02008721 Sponsor: Klinikum Großhadern Medical Center University of Munich,Represented by the Medical Director Prof. Dr. med. Burkhard Göke, Marchioninistraße 15 D-81377 Munich Principal Investigator: Prof. Dr. med. Günter Höglinger Department of Neurology, Klinikum rechts der Isar Technische Universität München Ismaninger Str. 22 D-81675 Munich; Contact: Yvonne Rödenbeck Trial Monitoring: Münchner Studienzentrum Klinikum rechts der Isar ,Technische Universität München, Ismaninger Str.22 D-81675 Munich Trial Monitoring: Prof. Dr. rer. nat. Ulrich Masnmann, Institute for Medical Informatics, Biometry and Epidemiology (IBE), Marchioninistraße 15 D-81377 Munich Trial Office: Deutsches Zentrum für Neurodegenerative Erkrankungen e.V., Max-Lebsche Platz 30, D-81377 Munich Source: Priv.-Doz. Dr. med. Johannes Levin Neurologische Klinik Ludwig-Maximilians-Universität München

PROMESA NCT02008721 - Telephone visit 1 (T1)

- 22.12.17 - 1 Formular, 7 Itemgruppen, 19 Datenelemente, 1 Sprache

Itemgruppen: Date of Telephone contact, Adverse event, Concomitant medication, Study medication, Laboratory test, Laboratory test, Signature of investigator

Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) NCT02008721 Short title: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach Study Code: PROMESA EudraCT-Number: 2012-000928-18 NCT02008721 Sponsor: Klinikum Großhadern Medical Center University of Munich,Represented by the Medical Director Prof. Dr. med. Burkhard Göke, Marchioninistraße 15 D-81377 Munich Principal Investigator: Prof. Dr. med. Günter Höglinger Department of Neurology, Klinikum rechts der Isar Technische Universität München Ismaninger Str. 22 D-81675 Munich; Contact: Yvonne Rödenbeck Trial Monitoring: Münchner Studienzentrum Klinikum rechts der Isar ,Technische Universität München, Ismaninger Str.22 D-81675 Munich Trial Monitoring: Prof. Dr. rer. nat. Ulrich Masnmann, Institute for Medical Informatics, Biometry and Epidemiology (IBE), Marchioninistraße 15 D-81377 Munich Trial Office: Deutsches Zentrum für Neurodegenerative Erkrankungen e.V., Max-Lebsche Platz 30, D-81377 Munich Source: Priv.-Doz. Dr. med. Johannes Levin Neurologische Klinik Ludwig-Maximilians-Universität München

Stichworte

Inhaltsverzeichnis

Ausgewählte Datenmodelle

Concomitant Medications Month 1- 3 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Concomitant Medications Month 1- 3

Concomitant Medications Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Concomitant Medications Screening

Efficacy of Formulation X and AVANDIA in Subjects with Type 2 Diabetes Mellitus 100723 - Additional Forms - Medication

Concomitant Medications Month 10- 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 10- 12

Concomitant Medications Month 7- 9 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 7- 9

Concomitant Medications Month 4- 6 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 4- 6

Concomitant Medications Month 1- 3 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 1- 3

Concomitant Medications Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Screening

PROMESA NCT02008721 - Concomitant Medication Record and Adverse Event Form

PROMESA NCT02008721 - Telephone visit 3 (T3)

PROMESA NCT02008721 - Telephone visit 2 (T2)

PROMESA NCT02008721 - Telephone visit 1 (T1)

Stichworte

Inhaltsverzeichnis

Ausgewählte Datenmodelle

Kontakt

Hilfe